Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / American Depository Shares, each of which represent twenty ordinary shares, no par value
-
Shares outstanding
-
6,111,111
-
Total 13F shares
-
10,195,650
-
Share change
-
+1,233,042
-
Total reported value
-
$25,692,234
-
Put/Call ratio
-
5.8%
-
Price per share
-
$2.52
-
Number of holders
-
27
-
Value change
-
+$3,108,586
-
Number of buys
-
12
-
Number of sells
-
9
Institutional Holders of Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO) as of Q2 2023
As of 30 Jun 2023,
Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,195,650 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Novo Holdings A/S, Cormorant Asset Management, LP, Soleus Capital Management, L.P., BlackRock Inc., MAI Capital Management, GEODE CAPITAL MANAGEMENT, LLC, Laurion Capital Management LP, BRIDGEWAY CAPITAL MANAGEMENT, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.